Active Studies and Recruitment

The Lakeside Healthcare Research and Innovation Unit has been set up to provide all our patients with the opportunity to take part in clinical research studies which are relevant to them.

Current Studies

Lakeside Healthcare Research and Innovation Unit

Anthos Therapeutics Lilac TIMI 76 - A study to evaluate the efficacy and safety of Abelacimab in high-risk patients with atrial fibrillation, who have been deemed unsuitable for oral anticoagulation. Contact us for more information
AZ Bax24 - A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension. Contact us for more information
AstraZeneca Flash - A Phase 2a, Randomised, Double-Blind, Placebo Controlled Study to Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate-to-Severe Uncontrolled Asthma. Contact us for more information
AstraZeneca Prospero - A Phase III, Multicentre, Randomised, Double-blind, Chronic dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. Contact us for more information
AstraZeneca Tharros - A Study Evaluating the Efficacy of Breztri/Trixeo on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease. Contact us for more information
AstraZeneca Titania - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. Contact us for more information
Bayer Alpine 1 - A study to learn about how well BAY3283142 works and its safety in participants with chronic kidney disease. Contact us for more information
Bellus Calm-1 - A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough. Contact us for more information
GSK Low Carbon Asthma - A study to assess and compare safety and tolerability of 3 months treatment with salbutamol administered via Metered Dose Inhaler (MDI) containing propellant HFA-152a or HFA-134a in participants ≥18 years of age with asthma. Contact us for more information
Moderna CMVibe - A Phase 1/2a study for a Cytomegalovirus (CMV) Vaccine in Adult and Paediatric Participants. Contact us for more information
Moderna Fluent - A Phase 3, Randomized, Observer-blind, Active-controlled, Case driven Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age. Contact us for more information
Moderna Nova - A Phase 3, Randomized, Observer-blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age. Contact us for more information
MSD MK00616-015 - A Phase 3 Randomised, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk. Contact us for more information
Pfizer BHV3000-406 - A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use. Contact us for more information
Pfizer BHV3000-407 - A Phase 4, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequate Response to Oral Preventive Medications. Contact us for more information

Recruitment

Titania Clinical Research Study: Clinical study, for patients diagnosed with COPD
This study will be investigating whether a treatment called MEDI3506 could help manage COPD exacerbations (often called flare-ups, where COPD symptoms get worse) in patients who are currently receiving treatment for COPD.

You may be suitable if you:

Have been diagnosed with COPD for at least one year before the start of the study.
Are 40 years of age or older.
Are a current smoker OR a former smoker.

What will the study involve:

Come on site clinics to receive study treatment.
Attend appointments to have tests and assessments.
Complete questionnaires related to your well-being throughout the study using an electronic hand held device.
At the end of study, you will be asked to attend a final follow up visit. (Study duration is approximately 28 weeks)